Cell therapy company Link Cell Therapies is launching with $60 million and a mission to develop potent CAR-T therapies that go after a range of tumors while avoiding patients' healthy tissue. The ...

Steep learning curve. Slight pinging when typing. Strange quirks in setup require extensive troubleshooting. Lots of odd choices and bugs. Modules are difficult to use when tented. I really wanted to ...

Third Arc Bio is paying $5 million upfront to use Adagene’s tech in hopes of creating two new masked T-cell engagers. Down the line, Adagene could make up to $840 million in development and commercial ...

The T-Create P31 CinemaPr is specialized 10Gbps storage with mount points and hardware for attaching to video gear. It’s also rugged and performs very well for its class. Designed for videographers ...

Community driven content discussing all aspects of software development from DevOps to design patterns. Ready to develop your first AWS Lambda function in Python? It really couldn’t be easier. The AWS ...

Biosafety hawks were initially optimistic that the incoming second Trump administration would at last place binding constraints on so-called "dangerous gain-of-function" research, in which pathogens ...

Think the Dow’s 30 powerhouses are all unstoppable money machines? Think again. Some are value-destroying black holes; others are relentless value creators. The data? Ruthless. The takeaway? Crystal ...

Zach began writing for CNET in November, 2021 after writing for a broadcast news station in his hometown, Cincinnati, for five years. You can usually find him reading and drinking coffee or watching a ...

Dems' goal isn't to make us safer, it's to create chaos so they can maintain power: Chicago Red founder Political activist Lattina Brown and Chicago Red founder and chair P-Rae Easley weigh in the ...

If you’re a Java developer and you haven’t built an AWS Lambda function before, you’ll be amazed by how easy it is to get your first serverless application up and running. To build your first Java AWS ...

Contrary to public concerns, receiving frequent COVID-19 booster vaccinations will not weaken the immune system, providing reassurance to vulnerable groups facing new variants. Study: No evidence of ...

This cross-sectional study included adults in remission after CAR T-cell therapy for multiple myeloma or B-cell lymphoma who were within 1-5 years post-treatment. We used bivariate analyses to measure ...